About Opiant Pharmaceuticals
Opiant Pharmaceuticals is a company based in Santa Monica (United States) founded in 2005 was acquired by Indivior in November 2022. The company has 31 employees. Opiant Pharmaceuticals offers products and services including Addiction Treatments. Opiant Pharmaceuticals operates in a competitive market with competitors including Indivior, Biotie, Ethypharm, Braeburn and Amygdala Neurosciences, among others.
- Headquarter Santa Monica, United States
- Employees 31
- Stage Public
- SectorsHealthcare
- Email••••••••
- Website opiant.com/en
- Social LinkedIn X
- Acquired by Indivior (Nov 2022)
- Legal Name Indivior Plc
Products & Services of Opiant Pharmaceuticals
Opiant Pharmaceuticals offers a comprehensive portfolio of products and services, including Addiction Treatments.
Medications for managing substance use disorders effectively.
Funding Insights of Opiant Pharmaceuticals
- Total Rounds 4
- Last Round Grant — $7.4M
- First Round $2.5M
(Mar 2016)
- Investors Count 5
All 4 funding rounds of Opiant Pharmaceuticals with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug 2022 | $7.4M | Grant | – | – | |
| Dec 2020 | $50M | Post-IPO | – | – | |
| Jan 2018 | $5.3M | Post-IPO | – | – | – |
| Mar 2016 | $2.5M | Post-IPO | – | – |
6 investors in total: 6 institutional.
Investors in Opiant Pharmaceuticals
Opiant Pharmaceuticals has secured backing from 6 investors, including institutional and venture fund investors. Prominent investors backing the company include Indivior, NIH and Kreos Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture debt is provided to growth-stage companies across multiple sectors. | 1998 | kreoscapital.com | London, United Kingdom | |
Pontifax Venture Capital is focused on life sciences investments. | – | pontifax.com | Herzeliya, Israel | |
Drug discovery services are provided to the biopharma sector. | 1887 | nih.gov | United States | |
BARDA is focused on developing medical countermeasures for public health security. | – | medicalcountermeasures.gov | United States | |
Therapies for emergency conditions are developed and reformulated. | 2014 | adaptpharma.com | Dublin, Ireland | |
Therapeutics for opioid addiction treatment are developed and commercialized. | 2014 | indivior.com | Richmond Hill, United States |
Investor details for Opiant Pharmaceuticals
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Opiant Pharmaceuticals
238 people are tracked at Opiant Pharmaceuticals (127 in leadership, 9 in board & advisors, 102 in team); the tracked headcount is 31.
| Name | Role | Group |
|---|---|---|
Jim Moats | Access Director, Health Systems And Criminal Justice Systems | Leadership |
Lauren Church | US Head Of Logistics And Compliance | Leadership |
Edward McAdam | Director, Government Pricing, Contracting Operations And Analytics | Leadership |
Ryan McClelland | Director Of Market Access | Leadership |
Jennifer Vice | Associate Director | Leadership |
Kelli R. Casagrande | Area Sales Director | Leadership |
Matthew Ludwig | Area Sales Director | Leadership |
Jens Orphal | Head Of Field Force | Leadership |
Stephen Harrell | Area Sales Director | Leadership |
Johan V. | Associate Director - Business Analytics | Leadership |
Scot Johnston | Senior Access Director, Western Pennslyvania | Leadership |
Bob Fanning | Access Director, Health Systems | Leadership |
Anne le-Moigne | Vp, Clinical & Data Sciences And Operations | Leadership |
Luis Johnson | Associate Director Systems & Controls | Leadership |
Scott Carfagnini | Area Sales Director | Leadership |
Alix van Meerwijk | Global Program Director | Leadership |
Dmitry Bunich | Head Of Finance, Supply (director) | Leadership |
Lisa Toth | Access Director, Criminal Justice Systems | Leadership |
Bruce Gilbert | Sr. Area Sales Director | Leadership |
Doug Cobarras | Commercial Head Of Sales West Region | Leadership |
218 more people are available in the full profile.
Complete people profiles for Opiant Pharmaceuticals
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Opiant Pharmaceuticals
5 dated milestones of Opiant Pharmaceuticals across 17 years, from founding to its latest funding, stage changes and deals.
- Founded Opiant Pharmaceuticals is founded.
- IPO Lists on the stock exchange (IPO).
- Funding First funding round of $2.5M.
- Funding Latest funding round, Grant, of $7.4M.
- Exit Acquired by Indivior.
Competitors of Opiant Pharmaceuticals
Opiant Pharmaceuticals operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Indivior, Biotie, Ethypharm, Braeburn and Amygdala Neurosciences, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| indivior.com | 2014 | Richmond Hill, United States | – | 1,051 | Therapeutics for opioid addiction treatment are developed and commercialized. | |
| biotie.com | 1998 | Turku, Finland | $149.81M | 27 | Drugs for neurodegenerative and psychiatric disorders are developed by Biotie. | |
| ethypharm.com | 1977 | Saint Cloud, France | $248.09M | – | Therapies for pain and addiction treatment are developed. | |
| braeburnrx.com | 2012 | Philadelphia, United States | $110M | – | Long-acting therapies for opioid addiction and chronic pain are developed. | |
| amygns.com | 2015 | San Francisco, United States | $7.05M | – | Therapies for substance use disorders are developed by Amygdala Neurosciences. | |
| 4p-pharma.com | 2014 | Lille, France | $18.49M | – | French Biotech startup that develops to clinical trial stage the molecules it has in-licensed | |
| cessationtherapeutics.com | 2017 | San Jose, United States | $6.76M | – | Developer of immunotherapy based vaccines to manage addictions | |
| titanpharm.com | 1992 | San Francisco, United States | – | 11 | A specialty pharmaceutical company developing proprietary therapeutics for select chronic diseases | |
| aelisfarma.com | 2013 | Bordeaux, France | $14.04M | – | Developer of small molecule drugs targeting CB1 receptor for CNS diseases |
Detailed competitors of Opiant Pharmaceuticals
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Opiant Pharmaceuticals
The website of Opiant Pharmaceuticals (opiant.com) receives about 1.7K visits a month.
- Monthly visits1.7K
▲ 428% vs previous month
Latest news on Opiant Pharmaceuticals
Complete news archive for Opiant Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Opiant Pharmaceuticals
10 companies that operate in the same segment as Opiant Pharmaceuticals (Neurology), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Novel biopharmaceutical medicines are developed for unmet medical needs. | 2003 | Dublin, Ireland | USD 265 M | USD 4.27 B | 2,800 | |
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Developer of therapeutics for psychiatric and neurologic diseases | 2002 | New York, New York, United States | USD 80.87 M | USD 250.31 M | 600 | |
Biologics platform developed for intracellular delivery in rare diseases. | 2016 | Boston, Massachusetts, United States | USD 175.25 M | USD 25.42 M | 183 | |
Developer of therapies for the treatment of musculoskeletal disorders | 2007 | Woburn, Massachusetts, United States | USD 62 M | USD 85.55 M | 692 | |
MR-interfaced ultrasound devices for cancer and neurology treatments are provided. | 1999 | Tirat Carmel, Haifa District, Israel | USD 574.2 M | – | – | |
AI-driven drug discovery platform for neurological diseases based on patients biomarkers | 2019 | San Francisco, California, United States | USD 144.72 M | – | 76 | |
Small molecule drugs for rare diseases are developed. | 1998 | South Plainfield, New Jersey, United States | USD 248.1 M | USD 1.73 B | 939 | |
Developer of small molecule therapeutics for endocrine and CNS disorders | 1992 | San Diego, California, United States | USD 10 M | USD 2.86 B | 1,800 | |
Developer of antibodies to treat complement-mediated neurodegenerative diseases | 2011 | San Francisco, California, United States | USD 256 M | – | 100 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Opiant Pharmaceuticals
Opiant Pharmaceuticals was founded in 2005 and raised its 1st funding round 11 years after it was founded.
Opiant Pharmaceuticals is headquartered in Santa Monica, United States. It is registered at Santa Monica, California, United States.
Opiant Pharmaceuticals has 31 employees.
Opiant Pharmaceuticals was founded in 2005 and is headquartered in Santa Monica, United States. Operations focus on the pharmaceutical sector, where therapeutics for addictive and eating disorders are developed. The lead product, NARCAN Nasal Spray, is indicated for opioid overdose reversal. Additional pipeline assets target binge eating disorder and cocaine use disorder, supporting clinical advancements in behavioral health treatments.
Opiant Pharmaceuticals's top competitors include Indivior, Ethypharm and Amygdala Neurosciences.
Opiant Pharmaceuticals offers Addiction Treatments.
Opiant Pharmaceuticals has 6 investors. Key investors include Indivior, NIH, Kreos Capital, ADAPT Pharma, and BARDA.
Opiant Pharmaceuticals operates through Indivior Plc.
Yes. Opiant Pharmaceuticals was acquired by Indivior in November 2022.